KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Petra BLAHOVCOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vit PROCHAZKA, Andrea JANIKOVA, Martina VASKOVA, Ester MEJSTRIKOVA, Roman KODET, Jan TRKA and Marek TRNENY. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2018, vol. 36, No 5, p. 773-778. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2550.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
Authors KLENER, Pavel (203 Czech Republic, guarantor), Eva FRONKOVA (203 Czech Republic), Marketa KALINOVA (203 Czech Republic), David BELADA (203 Czech Republic), Kristina FORSTEROVA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Petra BLAHOVCOVA (203 Czech Republic), Martin SIMKOVIC (203 Czech Republic), David ŠÁLEK (203 Czech Republic, belonging to the institution), Heidi MOCIKOVA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Andrea JANIKOVA (203 Czech Republic), Martina VASKOVA (203 Czech Republic), Ester MEJSTRIKOVA (203 Czech Republic), Roman KODET (203 Czech Republic), Jan TRKA (203 Czech Republic) and Marek TRNENY (203 Czech Republic).
Edition Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2018, 0278-0232.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.439
RIV identification code RIV/00216224:14110/18:00105802
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/hon.2550
UT WoS 000452625700007
Keywords in English elderly patients; maintenance rituximab; mantle cell lymphoma; minimal residual disease; PET-CT
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 17:38.
Abstract
Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
PrintDisplayed: 10/7/2024 06:14